Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment

Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy. Thus, changes in SV2A expression could be a critical factor in the response to LEV. Epilep...

Descripció completa

Dades bibliogràfiques

Autors principals:	Itzel Jatziri Contreras-García, Gisela Gómez-Lira, Bryan Víctor Phillips-Farfán, Luz Adriana Pichardo-Macías, Mercedes Edna García-Cruz, Juan Luis Chávez-Pacheco, Julieta G. Mendoza-Torreblanca
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2021-04-01
Col·lecció:	Brain Sciences
Matèries:	SV2A levetiracetam pharmacoresistance VGAT VGLUT temporal lobe epilepsy
Accés en línia:	https://www.mdpi.com/2076-3425/11/5/531
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!